The relationship of blood CDC42 level with Th1 cells, Th17 cells, inflammation markers, disease risk/activity, and treatment efficacy of rheumatoid arthritis

Yongji Li1 · Wendi Yang2 · Feng Wang2

Received: 10 October 2021 / Accepted: 11 November 2021 / Published online: 2 December 2021
© The Author(s) 2021

Abstract
Background  Cell division control protein 42 (CDC42) is reported to be involved in multiple inflammation processes by regulating T cell differentiation, maintaining immune cell homeostasis, and altering their function, while no relevant studies explored its clinical role in patients with rheumatoid arthritis (RA). Therefore, this study aimed to explore the correlation of CDC42 with Th1 and Th17 cells and its association with disease risk, activity, and treatment outcomes of RA.

Methods  After the enrollment of 95 active RA patients and 50 healthy subjects (HC), their CDC42, Th1 cells, and Th17 cells were assayed by RT-qPCR and flow cytometry, accordingly. For RA patients only, CDC42 was also detected at W6, and W12 after treatment. The treatment response and remission status were evaluated at W12.

Results  Compared to HC, CDC42 was reduced ($P < 0.001$), while Th1 cells ($P = 0.021$) and Th17 cells ($P < 0.001$) were increased in RA patients. Besides, CDC42 was negatively correlated with Th17 cells ($P < 0.001$), erythrocyte sedimentation rate (ESR) ($P = 0.012$), C-reactive protein ($P = 0.002$), and disease activity score in 28 joints (DAS28) ($P = 0.007$), but did not relate to Th1 cells or other disease features (all $P > 0.05$) in RA patients. Furthermore, CDC42 was elevated during treatment in RA patients ($P < 0.001$). Moreover, CDC42 increment at W12 correlated with treatment response ($P = 0.004$). Besides, CDC42 elevation at W0 ($P = 0.038$), W6 ($P = 0.001$), and W12 ($P < 0.001$) also linked with treatment remission.

Conclusion  CDC42 has the potential to serve as a biomarker to monitor disease activity and treatment efficacy in patients with RA.

Keywords  Cell division control protein 42 · Disease risk and activity · Rheumatoid arthritis · Th1 and Th17 cells · Treatment efficacy

Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation and autoantibodies [1]. Notably, RA places a significant burden on patients since it causes irreversible joint damage that may eventually lead to disability [1, 2]. Although various pharmacological interventions (including non-steroidal anti-inflammatory drugs, conventional synthetic disease-modified anti-rheumatoid drugs (cDMARDs) and biologics etc.) have been applied to manage RA, low treatment remission rate in RA patients has still been reported [3]. Thus, low treatment remission impairs the daily function and even long-term clinical outcomes of RA patients [4, 5]. Recently, several biomarkers (such as certain polymorphisms of B lymphocyte stimulator promoter, autoantibody profile, and anti-drug antibodies etc.) have been identified to predict treatment response in RA patients, which further individualizes RA management and improves their prognosis [6–8].

Cell division control protein 42 (CDC42), a type of small GTPase belonging to the Rho family, has been reported to be involved in regulating actin polymerization and epithelial polarity [9, 10]. In addition, CDC42 also participates in modulating immune response by interacting with neutrophils, T cells, and B cells to maintain their identity, promote
cell differentiation, and activate their function [11–14]. For instance, CDC42 suppresses T cell differentiation into T-helper 17 (Th17) cells leading to imbalance of Th17/regulatory T cells (Treg) and development of autoimmunity [12]. Moreover, deletion of CDC42 in naïve T cell promotes T cell differentiation into Th1 cells, CD8+ T cells, and memory T cells [14]. Furthermore, CDC42 reduces the inflammation characterized by decreased inflammatory cytokine production (such as interferon (IFN)-γ and tumor necrosis factor (TNF)-α) in an animal model of inflammatory bowel disease (IBD) [15]. In the clinical aspect, CDC42 correlates with disease risk and activity of pediatric IBD [16], while no relevant studies have reported the clinical role of CDC42 in patients with RA.

Therefore, the aim of this study was to explore the correlation of CDC42 with RA risk and its association with Th1 cells, Th17 cells, disease activity, and treatment outcomes in patients with RA.

Methods

Subjects

This prospective study was approved by the Institutional Research Ethics Committee. From January 2018 to July 2020, a total of 95 active RA patients who were treated in the hospital were consecutively enrolled in the study. The patients who meet the following criteria were eligible for enrollment: (a) diagnosed as RA according to the 2010 American College of Rheumatology criteria [17]; (b) age more than 18 years; (c) disease activity score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) more than 3.2; (d) willing to provide peripheral blood (PB) samples for the study use. Patients were excluded if they had the following conditions: (a) presented with active infections; (b) presented with active hepatitis B/C virus; (c) history of cancers or malignancies; (d) joint deformity; (e) during pregnancy or lactation. In addition, during the same period, 50 additional healthy subjects matched for age and gender to RA patients were recruited for the study as health controls (HC). To eliminate the potential sources of bias, the age of HC was limited within 40–70 years old, and the gender ratio of HC was 4:1 (female: male). The written informed consents were obtained from all subjects.

Collection of data and samples

Clinical characteristics of RA patients were recorded after enrollment, which included demographic characteristics, autoantibodies, and disease activity components. Also, PB samples of RA patients were collected at baseline (W0, then at week 6 (W6) and week 12 (W12) after beginning the treatment, which were used for separation of peripheral blood mononuclear cells (PBMCs) by gradient density centrifugation. For HC, PBMCs samples were also collected after admission to isolate PBMCs.

Treatment

Depending on the actual disease situation, the patients received corresponding treatment. Seventy-four patients received monotherapy or combination treatment with conventional disease-modifying antirheumatic drug (cDMARD), while 21 patients received biologics-based regimen, including tumor necrosis factor inhibitor (TNFi) and interleukin-6 inhibitor (IL-6i), with or without cDMARD combination.

Determination of CDC42 expression

PBMCs of all subjects were used to assess the expression of CDC42 by reverse transcription quantitative polymerase chain reaction (RT-qPCR). In brief, the total RNA was extracted from PBMCs using the QIAamp RNA Blood Mini Kit (Qiagen, Duesseldorf, Nordrhein-Westfalen, Germany). Then, reverse transcription was achieved using PrimeScript™ RT reagent Kit (Perfect Real Time) (Takara, Dalian, Liaoning, China). Subsequently, the PCR reaction utilized QuantiNova SYBR Green PCR Kit (Qiagen, Duesseldorf, Nordrhein-Westfalen, Germany). The relative expression of CDC42 was calculated by the $2^{-\Delta\Delta C_{t}}$ method using GAPDH as an internal reference. The detailed sequences of forward and reverse primers for CDC42 and GAPDH were in line with a previous study [18].

Determination of Th1 and Th17 cells

Th1 and Th17 cells (within CD4+ T cells, %) were determined by multicolor flow cytometric analysis using the HumanTh1/Th17 Phenotyping Kit (Becton, Dickinson and Company, Franklin Lake, NJ, USA). The experiment was carried out referring to complete procedure of the kit specification. Briefly, T helper cells were stimulated by phorbol myristate acetate (PMA) plus Ionomycin. Afterwards, the cells were transferred into flow rest tube for immunofluorescent staining with specific fluorescent antibodies. Then, the stained cells were analyzed by flow cytometric analysis using a fluorescence activated cell sorting (FACS) flow cytometer. Finally, Th1 and Th17 cells (within CD4+ T cells, %) were calculated.
Assessment of complete response and complete remission

According to the European League Against Rheumatism (EULAR) response criteria [19], complete response and complete remission were assessed at W6 and W12 after initiation of treatment, based on DAS28-ESR score, which was calculated by tender joint count (TJC), swollen joint count (SJC), and ESR, and the formula was as follows:

\[
\text{DAS28} \text{- ESR} = [0.56 \sqrt{TJC} + 0.28 \sqrt{SJC} + 0.70 \times \text{ln(ESR)}] \times 1.08 + 0.16
\]

Complete response was defined as a DAS28-ESR score decreased more than 1.2 from baseline, and complete remission was defined as a DAS28-ESR score of less than 2.6. The RA patients were classified as response and non-response as well as remission and non-remission, based on W12 response and remission status.

Statistical analysis

Statistical analysis and graph plotting were completed using SPSS 24.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6.01 software (GraphPad Software Inc., San Diego, CA, USA), respectively. A total of 9 (9.5%) patients lost follow-up during the study, and all of them had at least one follow-up record. The last observation carried forward (LOCF) method was applied to process the missing data, and all patients were included in the analysis. Comparison of CDC42 expression, Th1 cells (within CD4+ T cells, %), and Th17 cells (within CD4+ T cells, %) between two groups was assessed by Mann–Whitney U test, and receiver operating characteristic (ROC) curve was used for estimating their profiles in distinguishing different subjects. Correlation between two variables was analyzed by Spearman’s rank correlation test. Changes of CDC42 expression over time were determined by Friedman test, and comparisons of CDC42 expression between response and non-response patients as well as remission and non-remission patients were determined by Mann–Whitney U test. Statistical significance was concluded if there was a \( P \) value < 0.05 in the above analysis.

Results

RA patients’ clinical features

RA patients presented with a mean age of 54.8 ± 9.8 years, consisting of 77 (81.1%) females and 18 (18.9%) males. The mean disease duration of RA patients was 3.5 ± 3.3 years. In terms of autoantibodies, 76 (80.0%) RA patients were positive for rheumatoid factor (RF) and 56 (58.9%) RA patients were positive for anti-cyclic citrullinated peptide antibody (ACPA). Moreover, the mean DAS28-ESR score of RA patients was 5.0 ± 0.7. There were 79 (83.2%) RA patients who received methotrexate (MTX) treatment prior to our study. Regarding the treatment, 21 (22.1%) RA patients received biologics-based regimen, and 74 (77.9%) RA patients received cDMARDs therapy. Moreover, the detailed clinical features of RA patients are listed in Table 1.

CDC42, Th1 cells, and Th17 cells in RA patients and HC

Compared to HC, CDC42 was reduced \( (P < 0.001, \text{Fig. 1A}) \), whereas Th1 cells \( (P = 0.021, \text{Fig. 1B}) \) and

Table 1 Clinical features of RA patients

| Items                                      | RA patients (\( N = 95 \)) |
|-------------------------------------------|--------------------------|
| **Demographics**                          |                          |
| Age (years), mean ± SD                    | 54.8 ± 9.8               |
| Gender, No. (%)                           |                          |
| Female                                    | 77 (81.1)                |
| Male                                      | 18 (18.9)                |
| BMI (kg/m²), mean ± SD                    | 22.4 ± 2.8               |
| Disease duration (years), mean ± SD       | 3.5 ± 3.3                |
| **Autoantibodies**                        |                          |
| RF, No. (%)                               |                          |
| Positive                                  | 76 (80.0)                |
| Negative                                  | 19 (20.0)                |
| ACPA, No. (%)                             |                          |
| Positive                                  | 56 (58.9)                |
| Negative                                  | 39 (41.1)                |
| **Disease activity components**           |                          |
| TJC, median (IQR)                         | 6.0 (5.0–8.0)            |
| SJC, median (IQR)                         | 5.0 (3.0–7.0)            |
| ESR (mm/h), median (IQR)                  | 31.0 (23.2–45.1)         |
| CRP (mg/L), median (IQR)                  | 23.5 (11.2–42.5)         |
| DAS28-ESR score, mean ± SD                | 5.0 ± 0.7                |
| HAQ-DI score, mean ± SD                   | 1.2 ± 0.3                |
| **Treatment**                             |                          |
| History of MTX treatment, No. (%)         | 79 (83.2)                |
| Biologics-based regimen (TNFi or IL-6i), No. (%) | 21 (22.1) |
| cDMARD (monotherapy or combination), No. (%) | 74 (77.9) |

RA rheumatoid arthritis, \( SD \) standard deviation, \( BMI \) body mass index, \( RF \) rheumatoid factor, \( ACPA \) anti-cyclic citrullinated peptide antibody, \( TJC \) tender joint count, \( IQR \) interquartile range, \( SJC \) swollen joint count, \( ESR \) erythrocyte sedimentation rate, \( CRP \) C-reactive protein, \( DAS28-ESR \) disease activity score in 28 joints based on erythrocyte sedimentation rate, \( HAQ-DI \) health assessment questionnaire disability index, \( MTX \) methotrexate, \( TNFi \) tumor necrosis factor inhibitor, \( IL-6i \) interleukin-6 inhibitor, \( cDMARD \) conventional disease-modifying antirheumatic drug.
Th17 cells ($P < 0.001$, Fig. 1C) were increased in RA patients. Further ROC curve analyses showed that Th17 cells (area under curve (AUC): 0.821, 95% confidence interval (CI): 0.750–0.892), CDC42 (AUC: 0.776, 95% CI: 0.694–0.857), and Th1 cells (AUC: 0.617, 95% CI: 0.518–0.716) all could distinguish RA patients from HC (Fig. 1D).

**Correlation of CDC42 with Th1 cells and Th17 cells**

Although CDC42 was not correlated with Th1 cells ($r = -0.173, P = 0.093$, Fig. 2A), it was negatively correlated with Th17 cells ($r = -0.396, P < 0.001$, Fig. 2B) in RA patients. However, no correlation of CDC42 with Th1 cells ($r = -0.185, P = 0.198$, Fig. 2C) or Th17 cells ($r = -0.275, P = 0.053$, Fig. 2D) in HC was observed.

**Correlation of CDC42 with clinical features**

There was no correlation of CDC42 with age, gender, BMI, disease duration, RF status, ACPA status, TJC, SJC, or HAQ-DI score in RA patents (all $P > 0.050$, Fig. 3A–H, L), while CDC42 was negatively correlated with ESR ($r = -0.256, P = 0.012$, Fig. 3I), CRP ($r = -0.314, P = 0.002$, Fig. 3J), and DAS28-ESR score ($r = -0.274, P = 0.007$, Fig. 3K).

**Correlation of CDC42 longitudinal change with treatment efficacy**

CDC42 was elevated during treatment in RA patients ($P < 0.001$, Fig. 4A). Further subgroup analyses exhibited that CDC42 at W12 was increased in RA patients who experienced response at W12 compared to those who did not at W12 ($P = 0.004$, Fig. 4B). Moreover, CDC42 at W0...
CDC42, as a small GTPase, plays a critical role in intracellular signaling pathways, particularly in the regulation of actin cytoskeleton dynamics, cell polarity, and cell morphology [20]. Apart from its normal biological function, CDC42 has been reported being involved in the regulation of immune response, osteoclast formation, and myeloid lineage commitment [11–13, 21, 22]. In the clinical field, few studies have reported the clinical value of CDC42 in inflammation-mediated diseases, while only one study reported that CDC42 expression was reduced in activate IBD pediatric patients compared to controls; also it correlated with active status of pediatric IBD [16]. However, the clinical role of CDC42 in RA patients remains unclear. Therefore, this study was conducted and we discovered that CDC42 was reduced, while Th1 and Th17 cells were increased in RA patients compared to controls. Moreover, CDC42, Th1 cells, and Th17 cells could distinguish RA patients from controls. The possible reasons to explain these findings were as follows: (a) CDC42 suppressed the immune response via regulating T cell receptor and interleukin (IL)-7 receptor signaling pathways, which led to a reduction in systemic inflammation and lower RA risk [15, 23]. (b) Th1 and Th17 cell promoted inflammatory cytokine production (such as IFN-γ, IL-17, and IL-23), which led to elevated systematic inflammation and RA risk [24, 25].

Apart from the aberrant expression of CDC42 in inflammation-mediated diseases, its correlation with disease activity is also of great interest. For instance, CD42 was negatively correlated with disease activity reflected by pediatric Crohn’s disease activity index in pediatric IBD patients [16], although no relevant studies have reported the correlation of CDC42 with disease activity or inflammation in RA patients. In the present study, we revealed that CDC42 was negatively correlated with Th17 cells, ESR, CRP, and DAS28-ESR score in RA patients, which could be explained by the following. (a) CDC42 inhibited the differentiation of regulator T cell into Th17 cells, which resulted in a negative correlation between CDC42 and Th17 cells in RA patients [12]. (b) CDC42 suppressed immune response through multiple mechanisms (such as maintenance of T cell identity and regulation of T cell activation) as discussed earlier, which thereby led to reduced inflammation and disease activity in RA patients [11–13].

The identification of potential biomarkers to monitor disease progression and treatment efficacy is necessary for RA patients’ management, while there are no relevant studies reporting the correlation of CDC42 with treatment efficacy in RA patients. In order to explore the longitudinal change in CDC42 and its correlation with treatment efficacy in RA patients, multiple-time measurements (at W0, W6, and W12 after the initiation of treatment) of CDC42 were conducted in our study. Then, we observed an increase of CDC42 during treatment in RA patients. Also, the increment of CDC42 correlated with better treatment efficacy in RA patients, which could be explained by the following: elevated CDC42 was correlated with reduced systematic inflammation as mentioned earlier, which thereby led to better treatment efficacy in RA patients [12, 15].

Several issues were needed to be discussed. For instance, we recruited 95 RA patients and 50 HC since the main purpose of this study was to observe a longitudinal change of CDC42 level and its correlation with treatment response in RA patients, instead of the comparison of CDC42 level between RA patients and HC. Secondly, CDC42 regulated T cell differentiation into Th1 cells and Th17 cells, while it had little effect on regulating Th2 cells in autoimmune diseases; thus, we only detected Th1 cells, Th17 cells, and their secreted cytokines in RA patients instead of Th2 cells in the current study [12, 14]. Thirdly, CDC42 regulated immune response by interacting with neutrophils, B cells, and T cells in the bloodstream; therefore, high blood CDC42 might influence the chronic inflammation and proliferative status of synovial joint in RA patients, while this hypothesis needed further validation [11–13]. Fourthly, limited study reported the clinical value of CDC42 in immune diseases; thus, more attention should be paid to explore the correlation of CDC42 with disease risk and activity in patients with immune diseases. Finally, combined cDMARDs or biologics-based regimen was applied in treating RA patients who failed to respond to single cDMARD in the current study.

However, there were some limitations in the present study. For instance, the sample size in the present study was relatively small, where further study with a larger sample size to validate these findings was necessary. Moreover, we only detected the CDC42 level from PBMC, while its level from other biological samples (such as synovial tissue,
serum, exosome etc.) in RA patients was not determined. Furthermore, the age-/gender-matched disease control (such as patients with osteoarthritis) was not recruited in the current study where a comprehensive analysis of CDC42 expression among RA patients, disease control, and HC was needed.

In conclusion, CDC42 was reduced and negatively correlates with Th17 cells, inflammation, and disease activity in RA patients. Moreover, CDC42 was elevated during treatment and its increment correlates with better treatment outcomes in RA patients, indicating its potential clinical value for RA management.

**Declarations**

**Ethics approval and consent to participate** This prospective study was approved by the Institutional Research Ethics Committee of Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science. And the written informed consents were obtained from all subjects.

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8
2. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219. https://doi.org/10.1056/NEJMra1004965
3. van der Woude D, van der Helm-van Mil AHM (2018) Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol 32(2):174–187. https://doi.org/10.1016/j.berh.2018.10.005
4. Buch MH (2018) Defining refractory rheumatoid arthritis. Ann Rheum Dis 77(7):966–969. https://doi.org/10.1136/annrheumdis-2017-212862
5. Roodenrijks NMT, van der Goes MC, Welsing PMJ et al (2021) Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford) 60(8):3778–3788. https://doi.org/10.1093/rheumatology/kea860
6. de Moel EC, Derksen V, Stoecken G et al (2018) Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. Arthritis Res Ther 20(1):33. https://doi.org/10.1186/s13075-018-1520-4
7. Conti V, Corbi G, Costantino M et al (2020) Biomarkers to personalize the treatment of rheumatoid arthritis: focus on autoantibodies and pharmacogenetics. Biomolecules 10(12). https://doi.org/10.3390/biom10121672
8. Fabris M, Quartuccio L, Vital E et al (2013) The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis Rheum 65(1):88–97. https://doi.org/10.1002/art.37707
9. Pichaud F, Walther RF, Nunes de Almeida F (2019) Regulation of Cdc42 and its effectors in epithelial morphogenesis. J Cell Sci 132(10). https://doi.org/10.1242/jcs.217869
10. Reyes-Miguel T, Roa-Espitia AL, Baltierrez-Hoyos R et al (2020) CDC42 drives RHO A activity and actin polymerization during capacitation. Reproduction 160(3):393–404. https://doi.org/10.1530.REP-19-0577
11. Tackenberg H, Moller S, Filippi MD et al (2020) The small GTPase Cdc42 is a major regulator of neutrophil effector functions. Front Immunol 11:1197. https://doi.org/10.3389/fimmu.2020.01197
12. Kalim KW, Yang QJ, Li Y et al (2018) Reciprocal regulation of glycolysis-driven Th17 pathogenicity and regulatory T cell stability by Cdc42. J Immunol 200(7):2313–2326. https://doi.org/10.4049/jimmunol.1601765
13. Burbage M, Keppler SJ, Gasparrini F et al (2015) Cdc42 is a key regulator of B cell differentiation and is required for antiviral humoral immunity. J Exp Med 212(1):53–72. https://doi.org/10.1084/jem.20141143
14. Guo F, Zhang S, Tripathi P et al (2011) Distinct roles of Cdc42 in thymopoiesis and effector and memory T cell differentiation. PLoS ONE 6(3):e18002. https://doi.org/10.1371/journal.pone.0018002
15. Dong LM, Chen XW, He XX et al (2019) Cell division cycle protein 42 regulates the inflammatory response in mice bearing inflammatory bowel disease. Artif Cells Nanomed Biotechnol 47(1):1833–1838. https://doi.org/10.1080/21691401.2019.1596936
16. Tang WJ, Peng KY, Tang ZF et al (2018) MicroRNA-15a - cell division cycle 42 signaling pathway in pathogenesis of pediatric inflammatory bowel disease. World J Gastroenterol 24(46):5234–5245. https://doi.org/10.3748/wjg.v24.i46.5234
17. Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. https://doi.org/10.1002/art.27584
18. Wang Z, Liu J, Wang R et al (2020) Long non-coding RNA tau-regulated gene 1 (TUG1) downregulation constrains cell proliferation and invasion through regulating cell division cycle 42 (CDC42) expression via MiR–498 in esophageal squamous cell carcinoma cells. Med Sci Monit 26:e919714. https://doi.org/10.12659/MSM.919714
19. Van Gestel AM, Prevoo ML, Van't Hoof MA et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary. American College of Rheumatology and the World Health Organisation/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34–40. https://doi.org/10.1002/art.1780390105
20. Reiner DJ, Lundquist EA (2018) Small GTPases, WormBook 2018:1–65. https://doi.org/10.1895/wormbook.1.67.2
21. Itzstein C, Coxon FP, Rogers MJ (2011) The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases 2(3):117–130. https://doi.org/10.4161/sgtp.2.3.16453
22. Wirth F, Huck K, Lubosch A et al (2021) Cdc42 in osteirx-expressing cells alters osteoblast behavior and myeloid lineage commitment. Bone 153:116150. https://doi.org/10.1016/j.bone.2021.116150
23. Guo F, Hileman D, Tripathi P et al (2010) Coordination of IL-7 receptor and T-cell receptor signaling by cell-division cycle 42 in T-cell homeostasis. Proc Natl Acad Sci U S A 107(43):18505–18510. https://doi.org/10.1073/pnas.1010249107
24. Bunte K, Beikler T (2019) Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci 20(14). https://doi.org/10.3390/ijms20143394
25. Hirahara K, Nakayama T (2016) CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol 28(4):163–171. https://doi.org/10.1093/intimm/dxw006

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.